{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T10:35:42Z","timestamp":1794220542024,"version":"4.8.0"},"reference-count":110,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Shandong Technology Innovation Center of Exercise and Fitness"},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No.32171124"],"award-info":[{"award-number":["No.32171124"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No.32271180"],"award-info":[{"award-number":["No.32271180"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No.32171124"],"award-info":[{"award-number":["No.32171124"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No.32171124"],"award-info":[{"award-number":["No.32171124"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"DOI":"10.1186\/s40001-025-02840-9","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T23:41:49Z","timestamp":1751586109000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The role of HDAC6 in fibrosis: a novel and effective therapy strategy"],"prefix":"10.1186","volume":"30","author":[{"given":"Liangliang","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiankui","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,4]]},"reference":[{"key":"2840_CR1","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41573-019-0040-5","volume":"19","author":"X Zhao","year":"2020","unstructured":"Zhao X, Kwan JYY, Yip K, Liu PP, Liu FF. Targeting metabolic dysregulation for fibrosis therapy. Nat Rev Drug Discovery. 2020;19:57\u201375. https:\/\/doi.org\/10.1038\/s41573-019-0040-5.","journal-title":"Nat Rev Drug Discovery"},{"key":"2840_CR2","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41392-022-01070-3","volume":"7","author":"M Zhao","year":"2022","unstructured":"Zhao M, Wang L, Wang M, Zhou S, Lu Y, Cui H, Racanelli AC, Zhang L, Ye T, Ding B, et al. Targeting fibrosis, mechanisms and cilinical trials. Signal Transduct Target Ther. 2022;7:206. https:\/\/doi.org\/10.1038\/s41392-022-01070-3.","journal-title":"Signal Transduct Target Ther"},{"key":"2840_CR3","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.yjmcc.2014.02.015","volume":"70","author":"KB Schuetze","year":"2014","unstructured":"Schuetze KB, McKinsey TA, Long CS. Targeting cardiac fibroblasts to treat fibrosis of the heart: focus on HDACs. J Mol Cell Cardiol. 2014;70:100\u20137. https:\/\/doi.org\/10.1016\/j.yjmcc.2014.02.015.","journal-title":"J Mol Cell Cardiol"},{"key":"2840_CR4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1021\/acs.jmedchem.9b00924","volume":"63","author":"M Brindisi","year":"2020","unstructured":"Brindisi M, Saraswati A, Brogi S, Gemma S, Butini S, Campiani G. Old but gold: tracking the new guise of histone deacetylase 6 (HDAC6) enzyme as a biomarker and therapeutic target in rare diseases. J Med Chem. 2020;63:23\u201339. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b00924.","journal-title":"J Med Chem"},{"key":"2840_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.899140","author":"Y Shi","year":"2022","unstructured":"Shi Y, Li J, Chen H, Hu Y, Tang L, Zhou X, Tao M, Lv Z, Chen S, Qiu A, Liu N. Pharmacologic inhibition of histone deacetylase 6 prevents the progression of chlorhexidine gluconate-induced peritoneal fibrosis by blockade of M2 macrophage polarization. Front Immunol. 2022. https:\/\/doi.org\/10.3389\/fimmu.2022.899140.","journal-title":"Front Immunol"},{"key":"2840_CR6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s10020-018-0027-4","volume":"24","author":"B Ke","year":"2018","unstructured":"Ke B, Chen Y, Tu W, Ye T, Fang X, Yang L. Inhibition of HDAC6 activity in kidney diseases: a new perspective. Mol Med. 2018;24:33. https:\/\/doi.org\/10.1186\/s10020-018-0027-4.","journal-title":"Mol Med"},{"key":"2840_CR7","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1146\/annurev.biochem.70.1.81","volume":"70","author":"SY Roth","year":"2001","unstructured":"Roth SY, Denu JM, Allis CD. Histone acetyltransferases. Ann Rev Biochem. 2001;70:40. https:\/\/doi.org\/10.1146\/annurev.biochem.70.1.81.","journal-title":"Ann Rev Biochem"},{"key":"2840_CR8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/s0959-437x(00)00173-8","volume":"11","author":"R Marmorstein","year":"2001","unstructured":"Marmorstein R, Roth SY. Histone acetyltransferases: function, structure, and catalysis. Curr Opin Genet Dev. 2001;11:7. https:\/\/doi.org\/10.1016\/s0959-437x(00)00173-8.","journal-title":"Curr Opin Genet Dev"},{"key":"2840_CR9","doi-asserted-by":"publisher","first-page":"a018713","DOI":"10.1101\/cshperspect.a018713","volume":"6","author":"E Seto","year":"2014","unstructured":"Seto E, Yoshida M. Erasers of histone acetylation: the histone deacetylase enzymes. Cold Spring Harb Perspect Biol. 2014;6:a018713. https:\/\/doi.org\/10.1101\/cshperspect.a018713.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2840_CR10","doi-asserted-by":"publisher","first-page":"1426508","DOI":"10.3389\/fcell.2024.1426508","volume":"12","author":"HP Cheng","year":"2024","unstructured":"Cheng HP, Jiang SH, Cai J, Luo ZQ, Li XH, Feng DD. Histone deacetylases: potential therapeutic targets for idiopathic pulmonary fibrosis. Front Cell Dev Biol. 2024;12:1426508. https:\/\/doi.org\/10.3389\/fcell.2024.1426508.","journal-title":"Front Cell Dev Biol"},{"key":"2840_CR11","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/s41419-024-06972-4","volume":"15","author":"H Ni","year":"2024","unstructured":"Ni H, Chen M, Dong D, Zhou Y, Cao Y, Ge R, Luo X, Wang Y, Dong X, Zhou J, et al. CYLD\/HDAC6 signaling regulates the interplay between epithelial-mesenchymal transition and ciliary homeostasis during pulmonary fibrosis. Cell Death Dis. 2024;15:581. https:\/\/doi.org\/10.1038\/s41419-024-06972-4.","journal-title":"Cell Death Dis"},{"key":"2840_CR12","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.molcel.2005.04.021","volume":"18","author":"J Kovacs","year":"2005","unstructured":"Kovacs J, Murphy P, Gaillard S, Zhao X, Wu J, Nicchitta C, Yoshida M, Toft D, Pratt W, Yao T. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell. 2005;18:601\u20137. https:\/\/doi.org\/10.1016\/j.molcel.2005.04.021.","journal-title":"Mol Cell"},{"key":"2840_CR13","first-page":"4","volume":"23","author":"AG Charlotte Hubbert","year":"2002","unstructured":"Charlotte Hubbert AG, Shao R, Yoshiharu Kawaguchi AI, Nixon A, Yoshida M, Yao XFP. HDAC6 is a microtubule-associated deacetylase. Nature. 2002;23:4.","journal-title":"Nature"},{"key":"2840_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11050336","author":"M Ghiboub","year":"2021","unstructured":"Ghiboub M, Elfiky AMI, de Winther MPJ, Harker NR, Tough DF, de Jonge WJ. Selective targeting of epigenetic readers and histone deacetylases in autoimmune and inflammatory diseases: recent advances and future perspectives. J Personal Med. 2021. https:\/\/doi.org\/10.3390\/jpm11050336.","journal-title":"J Personal Med"},{"key":"2840_CR15","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.intimp.2013.03.016","volume":"16","author":"S Vishwakarma","year":"2013","unstructured":"Vishwakarma S, Iyer L, Muley M, Singh P, Shastry A, Saxena A, Kulathingal J, Vijaykanth G, Raghul J, Rajesh N, et al. Tubastatin, a selective histone deacetylase 6 inhibitor shows anti-inflammatory and anti-rheumatic effects. Int Immunopharmacol. 2013;16:72\u20138. https:\/\/doi.org\/10.1016\/j.intimp.2013.03.016.","journal-title":"Int Immunopharmacol"},{"key":"2840_CR16","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1113\/jphysiol.2011.224907","volume":"590","author":"J Lee","year":"2012","unstructured":"Lee J, Wei J, Liu W, Cheng J, Feng J, Yan Z. Histone deacetylase 6 gates the synaptic action of acute stress in prefrontal cortex. J Physiol. 2012;590:1535\u201346. https:\/\/doi.org\/10.1113\/jphysiol.2011.224907.","journal-title":"J Physiol"},{"key":"2840_CR17","doi-asserted-by":"publisher","first-page":"4223","DOI":"10.1360\/tb-2020-0644","volume":"65","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Yu S, Su J, Yan X, Sun L, Tian R, Xu L. HDAC6-HSP90 pathway-mediated protein folding and degradation regulates tumor cell proliferation and metastasis. Chin Sci Bull. 2020;65:4223\u201334. https:\/\/doi.org\/10.1360\/tb-2020-0644.","journal-title":"Chin Sci Bull"},{"key":"2840_CR18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1750-1326-8-7","volume":"8","author":"C Simoes-Pires","year":"2013","unstructured":"Simoes-Pires C, Zwick V, Nurisso A, Schenker E, Carrupt PA, Cuendet M. HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs? Mol Neurodegener. 2013;8:7. https:\/\/doi.org\/10.1186\/1750-1326-8-7.","journal-title":"Mol Neurodegener"},{"key":"2840_CR19","doi-asserted-by":"publisher","first-page":"114438","DOI":"10.1016\/j.biopha.2023.114438","volume":"161","author":"Y Zhu","year":"2023","unstructured":"Zhu Y, Feng M, Wang B, Zheng Y, Jiang D, Zhao L, Mamun MAA, Kang H, Nie H, Zhang X, et al. New insights into the non-enzymatic function of HDAC6. Biomed Pharmacother. 2023;161:114438. https:\/\/doi.org\/10.1016\/j.biopha.2023.114438.","journal-title":"Biomed Pharmacother"},{"key":"2840_CR20","doi-asserted-by":"publisher","first-page":"938391","DOI":"10.3389\/fphar.2022.938391","volume":"13","author":"Q Hou","year":"2022","unstructured":"Hou Q, Kan S, Wang Z, Shi J, Zeng C, Yang D, Jiang S, Liu Z. Inhibition of HDAC6 with CAY10603 ameliorates diabetic kidney disease by suppressing NLRP3 inflammasome. Front Pharmacol. 2022;13:938391. https:\/\/doi.org\/10.3389\/fphar.2022.938391.","journal-title":"Front Pharmacol"},{"key":"2840_CR21","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.ajpath.2013.11.027","volume":"184","author":"SA Gradilone","year":"2014","unstructured":"Gradilone SA, Habringer S, Masyuk TV, Howard BN, Masyuk AI, LaRusso NF. HDAC6 Is overexpressed in cystic cholangiocytes and its inhibition reduces cystogenesis. Am J Pathol. 2014;184:600\u20138. https:\/\/doi.org\/10.1016\/j.ajpath.2013.11.027.","journal-title":"Am J Pathol"},{"key":"2840_CR22","doi-asserted-by":"publisher","first-page":"3748","DOI":"10.3390\/cancers12123748","volume":"12","author":"A Claveria-Cabello","year":"2020","unstructured":"Claveria-Cabello A, Colyn L, Uriarte I, Latasa MU, Arechederra M, Herranz JM, Alvarez L, Urman JM, Martinez-Chantar ML, Banales JM, et al. Dual pharmacological targeting of HDACs and PDE5 inhibits liver disease progression in a mouse model of biliary inflammation and fibrosis. Cancers. 2020;12:3748. https:\/\/doi.org\/10.3390\/cancers12123748.","journal-title":"Cancers"},{"key":"2840_CR23","doi-asserted-by":"publisher","DOI":"10.1172\/jci148333ds1","author":"Y Lin","year":"2022","unstructured":"Lin Y, Major JL, Liebner T, Hourani Z, Travers JG, Wennersten SA, Haefner KR, Cavasin MA, Wilson CE, Jeong MY, Han Y, Gotthardt M, Ferguson SK, Ambardekar AV, Lam MPY, Choudhary C, Granzier HL, Woulfe KC, McKinsey TA. HDAC6 modulates myofibril stiffness and diastolic function of the heart. J Clin Investig. 2022. https:\/\/doi.org\/10.1172\/jci148333ds1.","journal-title":"J Clin Investig"},{"key":"2840_CR24","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1536\/ihj.20-703","volume":"62","author":"Y Sawa","year":"2021","unstructured":"Sawa Y, Matsushita N, Sato S, Ishida N, Saito M, Sanbe A, Morino Y, Taira E, Obara M, Hirose M. Chronic HDAC6 activation induces atrial fibrillation through atrial electrical and structural remodeling in transgenic mice. Int Heart J. 2021;62:616\u201326. https:\/\/doi.org\/10.1536\/ihj.20-703.","journal-title":"Int Heart J"},{"key":"2840_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.722638","author":"Y Shi","year":"2021","unstructured":"Shi Y, Tao M, Ni J, Tang L, Liu F, Chen H, Ma X, Hu Y, Zhou X, Qiu A, et al. Requirement of histone deacetylase 6 for interleukin-6 induced epithelial-mesenchymal transition, proliferation, and migration of peritoneal mesothelial cells. Front Pharmacol. 2021. https:\/\/doi.org\/10.3389\/fphar.2021.722638.","journal-title":"Front Pharmacol"},{"key":"2840_CR26","doi-asserted-by":"publisher","first-page":"9960","DOI":"10.1021\/acs.jmedchem.1c00184","volume":"64","author":"G Campiani","year":"2021","unstructured":"Campiani G, Cavella C, Osko J, Brindisi M, Relitti N, Brogi S, Saraswati A, Federico S, Chemi G, Maramai S, et al. Harnessing the role of HDAC6 in idiopathic pulmonary fibrosis: design, synthesis, structural analysis, and biological evaluation of potent inhibitors. J Med Chem. 2021;64:9960\u201388. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c00184.","journal-title":"J Med Chem"},{"key":"2840_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2025.108360","author":"Q Jishun","year":"2025","unstructured":"Jishun Q, Chao M, Xianchen Z, Yuxi G, Wenhui Q, Xinru Z, Enlong M, Yongnan X. Discovery of novel selective HDAC6 inhibitors via a scaffold hopping approach for the treatment of idiopathic pulmonary fibrosis (IPF) in vitro and in vivo. Bioorg Chem. 2025. https:\/\/doi.org\/10.1016\/j.bioorg.2025.108360.","journal-title":"Bioorg Chem"},{"key":"2840_CR28","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1126\/science.272.5260.408","volume":"272","author":"J Taunton","year":"1996","unstructured":"Taunton J, Hassig CA, Schreiber SL. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science. 1996;272:4. https:\/\/doi.org\/10.1126\/science.272.5260.408.","journal-title":"Science"},{"key":"2840_CR29","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1073\/pnas.96.9.4868","volume":"96","author":"CM Grozinger","year":"1999","unstructured":"Grozinger CM, Hassig CA, Schreiber SL. Three proteins define a class of human histone deacetylases related to yeast Hda1p. Proc Natl Acad Sci. 1999;96:6. https:\/\/doi.org\/10.1073\/pnas.96.9.4868.","journal-title":"Proc Natl Acad Sci"},{"key":"2840_CR30","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.tcb.2008.04.003","volume":"18","author":"A Valenzuela-Fernandez","year":"2008","unstructured":"Valenzuela-Fernandez A, Cabrero JR, Serrador JM, Sanchez-Madrid F. HDAC6: a key regulator of cytoskeleton, cell migration and cell-cell interactions. Trends Cell Biol. 2008;18:291\u20137. https:\/\/doi.org\/10.1016\/j.tcb.2008.04.003.","journal-title":"Trends Cell Biol"},{"key":"2840_CR31","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1128\/MCB.01154-06","volume":"28","author":"Y Zhang","year":"2008","unstructured":"Zhang Y, Kwon S, Yamaguchi T, Cubizolles F, Rousseaux S, Kneissel M, Cao C, Li N, Cheng HL, Chua K, et al. Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally. Mol Cell Biol. 2008;28:1688\u2013701. https:\/\/doi.org\/10.1128\/MCB.01154-06.","journal-title":"Mol Cell Biol"},{"key":"2840_CR32","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/nrg2485","volume":"10","author":"M Haberland","year":"2009","unstructured":"Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet. 2009;10:32\u201342. https:\/\/doi.org\/10.1038\/nrg2485.","journal-title":"Nat Rev Genet"},{"key":"2840_CR33","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00261.2020","author":"X Chen","year":"2020","unstructured":"Chen X, Yu C, Hou X, Li J, Li T, Qiu A, Liu N, Zhuang S. Histone deacetylase 6 inhibition mitigates renal fibrosis by suppressing TGF-\u03b2 and EGFR signaling pathways in obstructive nephropathy. Am J Physiol Renal Physiol. 2020. https:\/\/doi.org\/10.1152\/ajprenal.00261.2020.","journal-title":"Am J Physiol Renal Physiol"},{"key":"2840_CR34","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1124\/jpet.110.168385","volume":"335","author":"M Pang","year":"2010","unstructured":"Pang M, Zhuang S. Histone deacetylase: a potential therapeutic target for fibrotic disorders. J Pharmacol Exp Ther. 2010;335:266\u201372. https:\/\/doi.org\/10.1124\/jpet.110.168385.","journal-title":"J Pharmacol Exp Ther"},{"key":"2840_CR35","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1111\/febs.12079","volume":"280","author":"Y Li","year":"2013","unstructured":"Li Y, Shin D, Kwon SH. Histone deacetylase 6 plays a role as a distinct regulator of diverse cellular processes. FEBS J. 2013;280:775\u201393. https:\/\/doi.org\/10.1111\/febs.12079.","journal-title":"FEBS J"},{"key":"2840_CR36","doi-asserted-by":"publisher","first-page":"115327","DOI":"10.1016\/j.ejmech.2023.115327","volume":"254","author":"G Liu","year":"2023","unstructured":"Liu G, Mondal P, Sang N, Li Z, Ding W, Yang L, Liu Y, Birar V, Gomm A, Tanzi R, et al. Design, synthesis, and anti-inflammatory activity characterization of novel brain-permeable HDAC6 inhibitors. Eur J Med Chem. 2023;254:115327. https:\/\/doi.org\/10.1016\/j.ejmech.2023.115327.","journal-title":"Eur J Med Chem"},{"key":"2840_CR37","doi-asserted-by":"publisher","first-page":"21065","DOI":"10.1074\/jbc.M802786200","volume":"283","author":"B Shan","year":"2008","unstructured":"Shan B, Yao TP, Nguyen HT, Zhuo Y, Levy DR, Klingsberg RC, Tao H, Palmer ML, Holder KN, Lasky JA. Requirement of HDAC6 for transforming growth factor-\u03b21-induced epithelial-mesenchymal transition. J Biol Chem. 2008;283:21065\u201373. https:\/\/doi.org\/10.1074\/jbc.M802786200.","journal-title":"J Biol Chem"},{"key":"2840_CR38","doi-asserted-by":"publisher","first-page":"450","DOI":"10.4049\/jimmunol.1000964","volume":"187","author":"T Liu","year":"2011","unstructured":"Liu T, Baek HA, Yu H, Lee HJ, Park BH, Ullenbruch M, Liu J, Nakashima T, Choi YY, Wu GD, et al. FIZZ2\/RELM-beta induction and role in pulmonary fibrosis. J Immunol. 2011;187:450\u201361. https:\/\/doi.org\/10.4049\/jimmunol.1000964.","journal-title":"J Immunol"},{"key":"2840_CR39","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1136\/thoraxjnl-2014-206411","volume":"70","author":"M Korfei","year":"2015","unstructured":"Korfei M, Skwarna S, Henneke I, MacKenzie BA, Klymenko O, Saito S, Ruppert C, von der Beck D, Mahavadi P, Klepetko W, Bellusci S, Crestani B, Pullamsetti SS, Fink L, Seeger W, Holger Kr\u00e4mer O, Guenther A. Aberrant expression and activity of histone deacetylases in sporadic idiopathic pulmonary fibrosis. Thorax. 2015;70:11. https:\/\/doi.org\/10.1136\/thoraxjnl-2014-206411.","journal-title":"Thorax"},{"key":"2840_CR40","doi-asserted-by":"publisher","first-page":"e0186615","DOI":"10.1371\/journal.pone.0186615","volume":"12","author":"S Saito","year":"2017","unstructured":"Saito S, Zhuang Y, Shan B, Danchuk S, Luo F, Korfei M, Guenther A, Lasky JA. Tubastatin ameliorates pulmonary fibrosis by targeting the TGFbeta-PI3K-Akt pathway. PLoS ONE. 2017;12:e0186615. https:\/\/doi.org\/10.1371\/journal.pone.0186615.","journal-title":"PLoS ONE"},{"key":"2840_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/srep32257","author":"W Xiaojun","year":"2016","unstructured":"Xiaojun W, Yan L, Hong X, Xianghong Z, Shifeng L, Dingjie X, Xuemin G, Lijuan Z, Bonan Z, Zhongqiu W, Ruimin W, Brann D, Yang F. Acetylated \u03b1-tubulin regulated by N-acetyl-seryl-aspartyl-lysyl-proline(Ac-SDKP) exerts the anti-fibrotic effect in rat lung fibrosis induced by silica. Sci Rep. 2016. https:\/\/doi.org\/10.1038\/srep32257.","journal-title":"Sci Rep"},{"key":"2840_CR42","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12950-017-0168-1","volume":"14","author":"T Yokoyama","year":"2017","unstructured":"Yokoyama T, Yanagihara T, Suzuki K, Hamada N, Tsubouchi K, Ogata-Suetsugu S, Mikumo H, Ikeda-Harada C, Maeyama T, Kuwano K, Nakanishi Y. Depletion of club cells attenuates bleomycin-induced lung injury and fibrosis in mice. J Inflamm. 2017;14:20. https:\/\/doi.org\/10.1186\/s12950-017-0168-1.","journal-title":"J Inflamm"},{"key":"2840_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-14-381","author":"S Rajasekaran","year":"2013","unstructured":"Rajasekaran S, Reddy NM, Zhang W, Reddy SP. Expression profiling of genes regulated by Fra-1\/AP-1 transcription factor during bleomycin-induced pulmonary fibrosis. BMC Genom. 2013. https:\/\/doi.org\/10.1186\/1471-2164-14-381.","journal-title":"BMC Genom"},{"key":"2840_CR44","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s00011-016-0984-4","volume":"65","author":"Y Ren","year":"2016","unstructured":"Ren Y, Su X, Kong L, Li M, Zhao X, Yu N, Kang J. Therapeutic effects of histone deacetylase inhibitors in a murine asthma model. Inflamm Res. 2016;65:995\u20131008. https:\/\/doi.org\/10.1007\/s00011-016-0984-4.","journal-title":"Inflamm Res"},{"key":"2840_CR45","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1183\/09031936.00084808","volume":"34","author":"Z Wang","year":"2009","unstructured":"Wang Z, Chen C, Finger SN, Kwajah MMS, Jung M, Schwarz H, Swanson N, Lareu RR, Raghunath M. Suberoylanilide hydroxamic acid: a potential epigenetic therapeutic agent for lung fibrosis? Eur Respir J. 2009;34:145\u201355. https:\/\/doi.org\/10.1183\/09031936.00084808.","journal-title":"Eur Respir J"},{"key":"2840_CR46","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00411.2012.-Dysfunctional","author":"SM Rymut","year":"2013","unstructured":"Rymut SM, Harker A, Corey DA, Burgess JD, Sun H, Clancy JP, Kelley TJ. Reduced microtubule acetylation in cystic fibrosis epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2013. https:\/\/doi.org\/10.1152\/ajplung.00411.2012.-Dysfunctional.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2840_CR47","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1159\/000489367","volume":"46","author":"D Liu","year":"2018","unstructured":"Liu D, Zhu H, Gong L, Pu S, Wu Y, Zhang W, Huang G. Histone deacetylases promote ER stress induced epithelial mesenchymal transition in human lung epithelial cells. Cell Physiol Biochem. 2018;46:1821\u201334. https:\/\/doi.org\/10.1159\/000489367.","journal-title":"Cell Physiol Biochem"},{"key":"2840_CR48","doi-asserted-by":"publisher","first-page":"10282","DOI":"10.1038\/s41598-019-46555-4","volume":"9","author":"J Rosenjack","year":"2019","unstructured":"Rosenjack J, Hodges C, Darrah R, Kelley T. HDAC6 depletion improves cystic fibrosis mouse airway responses to bacterial challenge. Sci Rep. 2019;9:10282. https:\/\/doi.org\/10.1038\/s41598-019-46555-4.","journal-title":"Sci Rep"},{"key":"2840_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-03931-2","author":"SM Rymut","year":"2017","unstructured":"Rymut SM, Corey DA, Valerio DM, Erokwu BO, Flask CA, Kelley TJ, Hodges CA. Improved growth patterns in cystic fibrosis mice after loss of histone deacetylase 6. Sci Rep. 2017. https:\/\/doi.org\/10.1038\/s41598-017-03931-2.","journal-title":"Sci Rep"},{"key":"2840_CR50","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/bcpt.13505","volume":"128","author":"F Zheng","year":"2021","unstructured":"Zheng F, Zhu J, Zhang W, Fu Y, Lin Z. Thal protects against paraquat-induced lung injury through a microRNA-141\/HDAC6\/I\u03baB\u03b1-NF-\u03baB axis in rat and cell models. Basic Clin Pharmacol Toxicol. 2021;128:334\u201347. https:\/\/doi.org\/10.1111\/bcpt.13505.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2840_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2022.175349","author":"M Brindisi","year":"2022","unstructured":"Brindisi M, Barone S, Rossi A, Cassese E, Del Gaudio N, Morel \u00c1JF, Filocamo G, Alberico A, De Fino I, Gugliandolo D, Babaei M, Bove G, Croce M, Montesano C, Altucci L, Bragonzi A, Summa V. Efficacy of selective histone deacetylase 6 inhibition in mouse models of Pseudomonas aeruginosa infection: a new glimpse for reducing inflammation and infection in cystic fibrosis. Eur J Pharmacol. 2022. https:\/\/doi.org\/10.1016\/j.ejphar.2022.175349.","journal-title":"Eur J Pharmacol"},{"key":"2840_CR52","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1152\/ajplung.00247.2018","volume":"317","author":"H Menden","year":"2019","unstructured":"Menden H, Mabry SM, Noel-MacDonnell J, Rajasingh J, Ye SQ, Sampath V. Histone deacetylase 6 regulates endothelial MyD88-dependent canonical TLR signaling, lung inflammation, and alveolar remodeling in the developing lung. Am J Physiol Lung Cell Mol Physiol. 2019;317:15. https:\/\/doi.org\/10.1152\/ajplung.00247.2018.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"2840_CR53","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.3c00644","author":"WC Yu","year":"2023","unstructured":"Yu WC, Yeh TY, Ye CH, Chong PCT, Ho YH, So DK, Yap KY, Peng GR, Shao CH, Jagtap AD, et al. Discovery of HDAC6, HDAC8, and 6\/8 inhibitors and development of cell-based drug screening models for the treatment of TGF-beta-induced idiopathic pulmonary fibrosis. J Med Chem. 2023. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c00644.","journal-title":"J Med Chem"},{"key":"2840_CR54","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1161\/01.res.0000046452.67724.b8","volume":"91","author":"I Manabe","year":"2002","unstructured":"Manabe I, Shindo T, Nagai R. Gene expression in fibroblasts and fibrosis: involvement in cardiac hypertrophy. Circ Res. 2002;91:1103\u201313. https:\/\/doi.org\/10.1161\/01.res.0000046452.67724.b8.","journal-title":"Circ Res"},{"key":"2840_CR55","doi-asserted-by":"publisher","first-page":"392","DOI":"10.4070\/kcj.2016.0266","volume":"47","author":"HJ Kee","year":"2017","unstructured":"Kee HJ, Kim GR, Lin MQ, Choi SY, Ryu Y, Jin L, Piao ZH, Jeong MH. Expression of class I and class II a\/b histone deacetylase is dysregulated in hypertensive animal models. Korean Circ J. 2017;47:392\u2013400. https:\/\/doi.org\/10.4070\/kcj.2016.0266.","journal-title":"Korean Circ J"},{"key":"2840_CR56","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/s41392-023-01502-8","volume":"8","author":"X Li","year":"2023","unstructured":"Li X, Li C, Zhang W, Wang Y, Qian P, Huang H. Inflammation and aging: signaling pathways and intervention therapies. Signal Transduct Target Ther. 2023;8:239. https:\/\/doi.org\/10.1038\/s41392-023-01502-8.","journal-title":"Signal Transduct Target Ther"},{"key":"2840_CR57","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00011-016-0925-2","volume":"65","author":"H Tao","year":"2016","unstructured":"Tao H, Yang JJ, Shi KH, Li J. Epigenetic factors MeCP2 and HDAC6 control alpha-tubulin acetylation in cardiac fibroblast proliferation and fibrosis. Inflamm Res. 2016;65:415\u201326. https:\/\/doi.org\/10.1007\/s00011-016-0925-2.","journal-title":"Inflamm Res"},{"key":"2840_CR58","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1161\/HYPERTENSIONAHA.121.18935","volume":"79","author":"M Brandt","year":"2022","unstructured":"Brandt M, Dorschmann H, Khraisat S, Knopp T, Ringen J, Kalinovic S, Garlapati V, Siemer S, Molitor M, Gobel S, et al. Telomere shortening in hypertensive heart disease depends on oxidative DNA damage and predicts impaired recovery of cardiac function in heart failure. Hypertension. 2022;79:2173\u201384. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.121.18935.","journal-title":"Hypertension"},{"key":"2840_CR59","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1159\/000350148","volume":"37","author":"HJ Kee","year":"2013","unstructured":"Kee HJ, Bae EH, Park S, Lee KE, Suh SH, Kim SW, Jeong MH. HDAC inhibition suppresses cardiac hypertrophy and fibrosis in DOCA-salt hypertensive rats via regulation of HDAC6\/HDAC8 enzyme activity. Kidney Blood Press Res. 2013;37:229\u201339. https:\/\/doi.org\/10.1159\/000350148.","journal-title":"Kidney Blood Press Res"},{"key":"2840_CR60","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1159\/000438864","volume":"96","author":"B Lkhagva","year":"2015","unstructured":"Lkhagva B, Lin YK, Kao YH, Chazo TF, Chung CC, Chen SA, Chen YJ. Novel histone deacetylase inhibitor modulates cardiac peroxisome proliferator-activated receptors and inflammatory cytokines in heart failure. Pharmacology. 2015;96:184\u201391. https:\/\/doi.org\/10.1159\/000438864.","journal-title":"Pharmacology"},{"key":"2840_CR61","doi-asserted-by":"publisher","first-page":"607","DOI":"10.4196\/kjpp.2018.22.6.607","volume":"22","author":"Y Wu","year":"2018","unstructured":"Wu Y, Si F, Luo L, Jing F, Jiang K, Zhou J, Yi Q. The effect of melatonin on cardio fibrosis in juvenile rats with pressure overload and deregulation of HDACs. Korean J Physiol Pharmacol. 2018;22:607. https:\/\/doi.org\/10.4196\/kjpp.2018.22.6.607.","journal-title":"Korean J Physiol Pharmacol"},{"key":"2840_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.614878","author":"K Wenzel","year":"2021","unstructured":"Wenzel K, Kr\u00e4mer E, Geertz B, Carrier L, Felix SB, K\u00f6nemann S, Schlossarek S. A transgenic mouse model of eccentric left ventricular hypertrophy with preserved ejection fraction exhibits alterations in the autophagy-lysosomal pathway. Front Physiol. 2021. https:\/\/doi.org\/10.3389\/fphys.2021.614878.","journal-title":"Front Physiol"},{"key":"2840_CR63","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.yjmcc.2019.04.003","volume":"130","author":"RA Bagchi","year":"2019","unstructured":"Bagchi RA, Weeks KL. Histone deacetylases in cardiovascular and metabolic diseases. J Mol Cell Cardiol. 2019;130:151\u20139. https:\/\/doi.org\/10.1016\/j.yjmcc.2019.04.003.","journal-title":"J Mol Cell Cardiol"},{"key":"2840_CR64","doi-asserted-by":"publisher","first-page":"C338","DOI":"10.1152\/ajpcell.00409.2021","volume":"322","author":"A Kolski-Andreaco","year":"2022","unstructured":"Kolski-Andreaco A, Balut CM, Bertuccio CA, Wilson AS, Rivers WM, Liu X, Gandley RE, Straub AC, Butterworth MB, Binion D, Devor DC. Histone deacetylase inhibitors (HDACi) increase expression of KCa2.3 (SK3) in primary microvascular endothelial cells. Am J Physiol Cell Physiol. 2022;322:C338\u201353. https:\/\/doi.org\/10.1152\/ajpcell.00409.2021.","journal-title":"Am J Physiol Cell Physiol"},{"key":"2840_CR65","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.yjmcc.2013.12.013","volume":"67","author":"SM Williams","year":"2014","unstructured":"Williams SM, Golden-Mason L, Ferguson BS, Schuetze KB, Cavasin MA, Demos-Davies K, Yeager ME, Stenmark KR, McKinsey TA. Class I HDACs regulate angiotensin II-dependent cardiac fibrosis via fibroblasts and circulating fibrocytes. J Mol Cell Cardiol. 2014;67:112\u201325. https:\/\/doi.org\/10.1016\/j.yjmcc.2013.12.013.","journal-title":"J Mol Cell Cardiol"},{"key":"2840_CR66","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1038\/s41467-024-45440-7","volume":"15","author":"S Ranjbarvaziri","year":"2024","unstructured":"Ranjbarvaziri S, Zeng A, Wu I, Greer-Short A, Farshidfar F, Budan A, Xu E, Shenwai R, Kozubov M, Li C, et al. Targeting HDAC6 to treat heart failure with preserved ejection fraction in mice. Nat Commun. 2024;15:1352. https:\/\/doi.org\/10.1038\/s41467-024-45440-7.","journal-title":"Nat Commun"},{"key":"2840_CR67","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.yjmcc.2011.04.005","volume":"51","author":"DD Lemon","year":"2011","unstructured":"Lemon DD, Horn TR, Cavasin MA, Jeong MY, Haubold KW, Long CS, Irwin DC, McCune SA, Chung E, Leinwand LA, McKinsey TA. Cardiac HDAC6 catalytic activity is induced in response to chronic hypertension. J Mol Cell Cardiol. 2011;51:41\u201350. https:\/\/doi.org\/10.1016\/j.yjmcc.2011.04.005.","journal-title":"J Mol Cell Cardiol"},{"key":"2840_CR68","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1159\/000438781","volume":"133","author":"H Tao","year":"2016","unstructured":"Tao H, Yang JJ, Hu W, Shi KH, Li J. HDAC6 promotes cardiac fibrosis progression through suppressing RASSF1A expression. Cardiology. 2016;133:18\u201326. https:\/\/doi.org\/10.1159\/000438781.","journal-title":"Cardiology"},{"key":"2840_CR69","doi-asserted-by":"publisher","first-page":"8139","DOI":"10.1111\/jcmm.14684","volume":"23","author":"L Zhang","year":"2019","unstructured":"Zhang L, Deng M, Lu A, Chen Y, Chen Y, Wu C, Tan Z, Boini KM, Yang T, Zhu Q, Wang L. Sodium butyrate attenuates angiotensin II-induced cardiac hypertrophy by inhibiting COX2\/PGE2 pathway via a HDAC5\/HDAC6-dependent mechanism. J Cell Mol Med. 2019;23:8139\u201350. https:\/\/doi.org\/10.1111\/jcmm.14684.","journal-title":"J Cell Mol Med"},{"key":"2840_CR70","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00149.2014.-Little","author":"KM Demos-Davies","year":"2014","unstructured":"Demos-Davies KM, Feruguson BS, Cavasin MA, Mahaffey JH, Williams SM, Spiltoir JI, Schuetze KB, Horn TR, Chen B, Ferrara C, Scellini B, Piroddi N, Tesi C, Poggesi C, Jeong MY, McKinsey TA. HDAC6 contributes to pathological responses of heart and skeletal muscle to chronic angiotensin-II signaling. Am J Physiology-Heart Circ Physiol. 2014. https:\/\/doi.org\/10.1152\/ajpheart.00149.2014.-Little.","journal-title":"Am J Physiology-Heart Circ Physiol"},{"key":"2840_CR71","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.yjmcc.2015.03.010","volume":"83","author":"BS Ferguson","year":"2015","unstructured":"Ferguson BS, McKinsey TA. Non-sirtuin histone deacetylases in the control of cardiac aging. J Mol Cell Cardiol. 2015;83:14\u201320. https:\/\/doi.org\/10.1016\/j.yjmcc.2015.03.010.","journal-title":"J Mol Cell Cardiol"},{"key":"2840_CR72","doi-asserted-by":"publisher","first-page":"860588","DOI":"10.3389\/fphar.2022.860588","volume":"13","author":"XY Yu","year":"2022","unstructured":"Yu XY, Sun Q, Zhang YM, Zou L, Zhao YY. TGF-beta\/Smad signaling pathway in tubulointerstitial fibrosis. Front Pharmacol. 2022;13:860588. https:\/\/doi.org\/10.3389\/fphar.2022.860588.","journal-title":"Front Pharmacol"},{"key":"2840_CR73","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/ki.2013.372","volume":"85","author":"B Wang","year":"2014","unstructured":"Wang B, Jha JC, Hagiwara S, McClelland AD, Jandeleit-Dahm K, Thomas MC, Cooper ME, Kantharidis P. Transforming growth factor-\u03b21-mediated renal fibrosis is dependent on the regulation of transforming growth factor receptor 1 expression by let-7b. Kidney Int. 2014;85:352\u201361. https:\/\/doi.org\/10.1038\/ki.2013.372.","journal-title":"Kidney Int"},{"key":"2840_CR74","doi-asserted-by":"publisher","DOI":"10.3390\/cells11243951","author":"L Shi","year":"2022","unstructured":"Shi L, Song Z, Li C, Deng F, Xia Y, Huang J, Wu X, Zhu J. HDAC6 inhibition alleviates ischemia- and cisplatin-induced acute kidney injury by promoting autophagy. Cells. 2022. https:\/\/doi.org\/10.3390\/cells11243951.","journal-title":"Cells"},{"key":"2840_CR75","doi-asserted-by":"publisher","first-page":"986405","DOI":"10.3389\/fmolb.2022.986405","volume":"9","author":"J Wang","year":"2022","unstructured":"Wang J, Li J, Zhang X, Zhang M, Hu X, Yin H. Molecular mechanisms of histone deacetylases and inhibitors in renal fibrosis progression. Front Mol Biosci. 2022;9:986405. https:\/\/doi.org\/10.3389\/fmolb.2022.986405.","journal-title":"Front Mol Biosci"},{"key":"2840_CR76","doi-asserted-by":"publisher","first-page":"312","DOI":"10.23876\/j.krcp.22.274","volume":"42","author":"MJ Kong","year":"2023","unstructured":"Kong MJ, Han SJ, Seu SY, Han KH, Lipschutz JH, Park KM. Shortening of primary cilia length is associated with urine concentration in the kidneys. Kidney Res Clin Pract. 2023;42:312\u201324. https:\/\/doi.org\/10.23876\/j.krcp.22.274.","journal-title":"Kidney Res Clin Pract"},{"key":"2840_CR77","doi-asserted-by":"publisher","first-page":"e0167340","DOI":"10.1371\/journal.pone.0167340","volume":"11","author":"U Sen","year":"2016","unstructured":"Sen U, Choi SY, Piao ZH, Jin L, Kim JH, Kim GR, Ryu Y, Lin MQ, Kim H-S, Kee HJ, Jeong MH. Piceatannol attenuates renal fibrosis induced by unilateral ureteral obstruction via downregulation of histone deacetylase 4\/5 or p38-MAPK signaling. PLoS ONE. 2016;11:e0167340. https:\/\/doi.org\/10.1371\/journal.pone.0167340.","journal-title":"PLoS ONE"},{"key":"2840_CR78","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.vph.2015.04.006","volume":"72","author":"SY Choi","year":"2015","unstructured":"Choi SY, Ryu Y, Kee HJ, Cho SN, Kim GR, Cho JY, Kim HS, Kim IK, Jeong MH. Tubastatin A suppresses renal fibrosis via regulation of epigenetic histone modification and Smad3-dependent fibrotic genes. Vascul Pharmacol. 2015;72:130\u201340. https:\/\/doi.org\/10.1016\/j.vph.2015.04.006.","journal-title":"Vascul Pharmacol"},{"key":"2840_CR79","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.kint.2016.01.026","volume":"90","author":"L Cebotaru","year":"2016","unstructured":"Cebotaru L, Liu Q, Yanda MK, Boinot C, Outeda P, Huso DL, Watnick T, Guggino WB, Cebotaru V. Inhibition of histone deacetylase 6 activity reduces cyst growth in polycystic kidney disease. Kidney Int. 2016;90:90\u20139. https:\/\/doi.org\/10.1016\/j.kint.2016.01.026.","journal-title":"Kidney Int"},{"key":"2840_CR80","doi-asserted-by":"publisher","first-page":"11513","DOI":"10.1074\/jbc.RA118.001846","volume":"293","author":"MK Yanda","year":"2018","unstructured":"Yanda MK, Liu Q, Cebotaru L. A potential strategy for reducing cysts in autosomal dominant polycystic kidney disease with a CFTR corrector. J Biol Chem. 2018;293:11513\u201326. https:\/\/doi.org\/10.1074\/jbc.RA118.001846.","journal-title":"J Biol Chem"},{"key":"2840_CR81","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1168848","author":"Q Zhang","year":"2023","unstructured":"Zhang Q, Zhang W, Chang S. HDAC6 inhibition: a significant potential regulator and therapeutic option to translate into clinical practice in renal transplantation. Front Immunol. 2023. https:\/\/doi.org\/10.3389\/fimmu.2023.1168848.","journal-title":"Front Immunol"},{"key":"2840_CR82","doi-asserted-by":"publisher","first-page":"F502","DOI":"10.1152\/ajprenal.00546.2016","volume":"312","author":"Y Shi","year":"2017","unstructured":"Shi Y, Xu L, Tang J, Fang L, Ma S, Ma X, Nie J, Pi X, Qiu A, Zhuang S, Liu N. Inhibition of HDAC6 protects against rhabdomyolysis-induced acute kidney injury. Am J Physiol Renal Physiol. 2017;312:F502\u201315. https:\/\/doi.org\/10.1152\/ajprenal.00546.2016.","journal-title":"Am J Physiol Renal Physiol"},{"key":"2840_CR83","doi-asserted-by":"publisher","first-page":"17897","DOI":"10.1074\/jbc.M117.803775","volume":"292","author":"MK Yanda","year":"2017","unstructured":"Yanda MK, Liu Q, Cebotaru V, Guggino WB, Cebotaru L. Histone deacetylase 6 inhibition reduces cysts by decreasing cAMP and Ca(2+) in knock-out mouse models of polycystic kidney disease. J Biol Chem. 2017;292:17897\u2013908. https:\/\/doi.org\/10.1074\/jbc.M117.803775.","journal-title":"J Biol Chem"},{"key":"2840_CR84","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1016\/j.bbadis.2018.02.001","volume":"1864","author":"MR Noh","year":"2018","unstructured":"Noh MR, Woo CH, Park MJ, In Kim J, Park KM. Ablation of C\/EBP homologous protein attenuates renal fibrosis after ureteral obstruction by reducing autophagy and microtubule disruption. Biochimica et biophysica acta. Mol Basis Dis. 2018;1864:1634\u201341. https:\/\/doi.org\/10.1016\/j.bbadis.2018.02.001.","journal-title":"Mol Basis Dis"},{"key":"2840_CR85","doi-asserted-by":"publisher","first-page":"104880","DOI":"10.1016\/j.ebiom.2023.104880","volume":"98","author":"B Wang","year":"2023","unstructured":"Wang B, Tang C, Lin E, Jia X, Xie G, Li P, Li D, Yang Q, Guo X, Cao C, et al. NIR-II fluorescence-guided liver cancer surgery by a small molecular HDAC6 targeting probe. EBioMedicine. 2023;98:104880. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104880.","journal-title":"EBioMedicine"},{"key":"2840_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.joim.2023.08.002","author":"YQ Zhang","year":"2023","unstructured":"Zhang YQ, Shi CX, Zhang DM, Zhang LY, Wang LW, Gong ZJ. Sulforaphane, an NRF2 agonist, alleviates ferroptosis in acute liver failure by regulating HDAC6 activity. J Integr Med. 2023. https:\/\/doi.org\/10.1016\/j.joim.2023.08.002.","journal-title":"J Integr Med"},{"key":"2840_CR87","first-page":"13","volume":"50","author":"F Guo","year":"2023","unstructured":"Guo F, Lei N, Huang R, et al. Study on the role and mechanism of HDAC6 in Cd-induced inflammation and fibrosis in mice liver. Biol Bull Russ Acad Sci. 2023;50:13.","journal-title":"Biol Bull Russ Acad Sci"},{"key":"2840_CR88","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.biochi.2015.06.016","volume":"116","author":"PJ Chen","year":"2015","unstructured":"Chen PJ, Huang C, Meng XM, Li J. Epigenetic modifications by histone deacetylases: biological implications and therapeutic potential in liver fibrosis. Biochimie. 2015;116:61\u20139. https:\/\/doi.org\/10.1016\/j.biochi.2015.06.016.","journal-title":"Biochimie"},{"key":"2840_CR89","doi-asserted-by":"publisher","DOI":"10.1111\/febs.70062","author":"MT Borrello","year":"2025","unstructured":"Borrello MT, Ruzic D, Paish H, Graham E, Collins AL, Scott R, Higginbotham S, Radovic B, Nelson G, Bulmer D, et al. Pharmacological manipulation of liver fibrosis progression using novel HDAC6 inhibitors. FEBS J. 2025. https:\/\/doi.org\/10.1111\/febs.70062.","journal-title":"FEBS J"},{"key":"2840_CR90","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.hbpd.2018.09.013","volume":"17","author":"Y Wang","year":"2018","unstructured":"Wang Y, Zhao L, Jiao FZ, Zhang WB, Chen Q, Gong ZJ. Histone deacetylase inhibitor suberoylanilide hydroxamic acid alleviates liver fibrosis by suppressing the transforming growth factor-\u03b21 signal pathway. Hepatobiliary Pancreat Dis Int. 2018;17:423\u20139. https:\/\/doi.org\/10.1016\/j.hbpd.2018.09.013.","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"2840_CR91","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1080\/15548627.2021.1895658","volume":"18","author":"Y Filali-Mouncef","year":"2022","unstructured":"Filali-Mouncef Y, Hunter C, Roccio F, Zagkou S, Dupont N, Primard C, Proikas-Cezanne T, Reggiori F. The menage a trois of autophagy, lipid droplets and liver disease. Autophagy. 2022;18:50\u201372. https:\/\/doi.org\/10.1080\/15548627.2021.1895658.","journal-title":"Autophagy"},{"key":"2840_CR92","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/s41419-022-05398-0","volume":"13","author":"G Bontempi","year":"2022","unstructured":"Bontempi G, Terri M, Garbo S, Montaldo C, Mariotti D, Bordoni V, Valente S, Zwergel C, Mai A, Marchetti A, et al. Restoration of WT1\/miR-769-5p axis by HDAC1 inhibition promotes MMT reversal in mesenchymal-like mesothelial cells. Cell Death Dis. 2022;13:965. https:\/\/doi.org\/10.1038\/s41419-022-05398-0.","journal-title":"Cell Death Dis"},{"key":"2840_CR93","doi-asserted-by":"publisher","first-page":"88730","DOI":"10.18632\/oncotarget.20982","volume":"8","author":"L Xu","year":"2017","unstructured":"Xu L, Liu N, Gu H, Wang H, Shi Y, Ma X, Ma S, Ni J, Tao M, Qiu A, Zhuang S. Histone deacetylase 6 inhibition counteracts the epithelial-mesenchymal transition of peritoneal mesothelial cells and prevents peritoneal fibrosis. Oncotarget. 2017;8:88730\u201350. https:\/\/doi.org\/10.18632\/oncotarget.20982.","journal-title":"Oncotarget"},{"key":"2840_CR94","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1080\/0886022X.2020.1811119","volume":"42","author":"Y Shi","year":"2020","unstructured":"Shi Y, Ni J, Tao M, Ma X, Wang Y, Zang X, Hu Y, Qiu A, Zhuang S, Liu N. Elevated expression of HDAC6 in clinical peritoneal dialysis patients and its pathogenic role on peritoneal angiogenesis. Ren Fail. 2020;42:890\u2013901. https:\/\/doi.org\/10.1080\/0886022X.2020.1811119.","journal-title":"Ren Fail"},{"key":"2840_CR95","doi-asserted-by":"publisher","first-page":"e0184302","DOI":"10.1371\/journal.pone.0184302","volume":"12","author":"EC Costalonga","year":"2017","unstructured":"Costalonga EC, de Freitas LJ, Aragone D, Silva FMO, Noronha IL. Anti-fibrotic effects of valproic acid in experimental peritoneal fibrosis. PLoS ONE. 2017;12:e0184302. https:\/\/doi.org\/10.1371\/journal.pone.0184302.","journal-title":"PLoS ONE"},{"key":"2840_CR96","doi-asserted-by":"publisher","first-page":"8492","DOI":"10.1038\/s41598-018-26319-2","volume":"8","author":"L Rossi","year":"2018","unstructured":"Rossi L, Battistelli C, de Turris V, Noce V, Zwergel C, Valente S, Moioli A, Manzione A, Palladino M, Bordoni V, et al. HDAC1 inhibition by MS-275 in mesothelial cells limits cellular invasion and promotes MMT reversal. Sci Rep. 2018;8:8492. https:\/\/doi.org\/10.1038\/s41598-018-26319-2.","journal-title":"Sci Rep"},{"key":"2840_CR97","doi-asserted-by":"publisher","first-page":"5892","DOI":"10.12659\/MSM.916313","volume":"25","author":"KH Liu","year":"2019","unstructured":"Liu KH, Fu J, Zhou N, Yin W, Yang YY, Ouyang SX, Liang YM. 1,25-dihydroxyvitamin D3 prevents epithelial-mesenchymal transition of HMrSV5 human peritoneal mesothelial cells by inhibiting histone deacetylase 3 (HDAC3) and increasing vitamin D receptor (VDR) expression through the Wnt\/beta-catenin signaling pathway. Med Sci Monit. 2019;25:5892\u2013902. https:\/\/doi.org\/10.12659\/MSM.916313.","journal-title":"Med Sci Monit"},{"key":"2840_CR98","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-023-00807-x","author":"H Linda","year":"2023","unstructured":"Linda H, Frank T. Hepatic inflammatory responses in liver fibrosis. Nat Rev Gastroenterol Hepatol. 2023. https:\/\/doi.org\/10.1038\/s41575-023-00807-x.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2840_CR99","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0263-2023","author":"PO Learta","year":"2024","unstructured":"Learta PO, Maximiliano Ruben F, Ulrich M, Susanne H. The guardians of pulmonary harmony: alveolar macrophages orchestrating the symphony of lung inflammation and tissue homeostasis. Eur Respir Rev. 2024. https:\/\/doi.org\/10.1183\/16000617.0263-2023.","journal-title":"Eur Respir Rev"},{"key":"2840_CR100","doi-asserted-by":"publisher","DOI":"10.1161\/circresaha.124.323658","author":"H Ingo","year":"2024","unstructured":"Ingo H, Stefan F, Nikolaos GF. Repair of the infarcted heart: cellular effectors, molecular mechanisms and therapeutic opportunities. Circ Res. 2024. https:\/\/doi.org\/10.1161\/circresaha.124.323658.","journal-title":"Circ Res"},{"key":"2840_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.08.010","author":"I Takuya","year":"2023","unstructured":"Takuya I, Akira I, Hiroyuki Y, Keisuke O, Naohiro T, Keita PM, Shoko O, Yukiko K, Takaya H, Sayaka S, et al. Matrix metalloproteinase-10 deficiency has protective effects against peritoneal inflammation and fibrosis via transcription factor NF\u03ba\u0392 pathway inhibition. Kidney Int. 2023. https:\/\/doi.org\/10.1016\/j.kint.2023.08.010.","journal-title":"Kidney Int"},{"key":"2840_CR102","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01544-2023","author":"MM Masum","year":"2025","unstructured":"Masum MM, Ghani SABA, Dasan Mary C, Hanumakumar B, Uthayanan N, Ashwatthaman S, Wai Shiu FW, Manvendra KS. YAP\/TAZ are crucial regulator of macrophage-mediated pulmonary inflammation and fibrosis after bleomycin-induced injury. Eur Resp J. 2025. https:\/\/doi.org\/10.1183\/13993003.01544-2023.","journal-title":"Eur Resp J"},{"key":"2840_CR103","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.06.016","author":"T Vlad","year":"2024","unstructured":"Vlad T, Gyongyi S, Wajahat M, Thomas R. Inflammasomes in chronic liver disease: hepatic injury, fibrosis progression and systemic inflammation. J Hepatol. 2024. https:\/\/doi.org\/10.1016\/j.jhep.2024.06.016.","journal-title":"J Hepatol"},{"key":"2840_CR104","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-019-0110-2","author":"T Patrick Ming-Kuen","year":"2019","unstructured":"Patrick Ming-Kuen T, Nikolic-Paterson DJ, Hui-Yao L. Macrophages: versatile players in renal inflammation and fibrosis. Nat Rev Nephrol. 2019. https:\/\/doi.org\/10.1038\/s41581-019-0110-2.","journal-title":"Nat Rev Nephrol"},{"key":"2840_CR105","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34831-3","author":"O Alexis","year":"2022","unstructured":"Alexis O, Aymeric RC, Edwige B, Isabella S, Yann-Ga\u00ebl G, Vincent M, Laetitia M, Remi M, Pascal L, Bernard JJ, Laurent S. Pharmacological inhibition of HDAC6 improves muscle phenotypes in dystrophin-deficient mice by downregulating TGF-\u03b2 via Smad3 acetylation. Nat Commun. 2022. https:\/\/doi.org\/10.1038\/s41467-022-34831-3.","journal-title":"Nat Commun"},{"key":"2840_CR106","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2020.08.013","author":"Z Yijing","year":"2020","unstructured":"Yijing Z, Yuemiao C, Xiaolang L, Qihao W, Gaole D, Yang Y, Kehe Y, Weiyang G. Inhibition of histone deacetylase 6 by Tubastatin A attenuates the progress of osteoarthritis via improving mitochondrial function. Am J Pathol. 2020. https:\/\/doi.org\/10.1016\/j.ajpath.2020.08.013.","journal-title":"Am J Pathol"},{"key":"2840_CR107","doi-asserted-by":"publisher","DOI":"10.3390\/biom10030487","author":"K Tzavlaki","year":"2020","unstructured":"Tzavlaki K, Moustakas A. TGF-beta signaling. Biomolecules. 2020. https:\/\/doi.org\/10.3390\/biom10030487.","journal-title":"Biomolecules"},{"key":"2840_CR108","doi-asserted-by":"publisher","first-page":"31086","DOI":"10.1038\/srep31086","volume":"6","author":"B Deskin","year":"2016","unstructured":"Deskin B, Lasky J, Zhuang Y, Shan B. Requirement of HDAC6 for activation of Notch1 by TGF-beta1. Sci Rep. 2016;6:31086. https:\/\/doi.org\/10.1038\/srep31086.","journal-title":"Sci Rep"},{"key":"2840_CR109","doi-asserted-by":"publisher","DOI":"10.1620\/tjem.2025.J040","author":"Y Wang","year":"2025","unstructured":"Wang Y, Yang L, Wang T, Li X, Zhang X. Tubacin decelerates TGF-\u03b21-induced pro-fibrotic effects on human dermal fibroblasts by regulating HDAC6-mediated deacetylation of \u03b1-tubulin and Hsp90. Tohoku J Exp Med. 2025. https:\/\/doi.org\/10.1620\/tjem.2025.J040.","journal-title":"Tohoku J Exp Med"},{"key":"2840_CR110","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aam7510","author":"M Majora","year":"2018","unstructured":"Majora M, Sondenheimer K, Knechten M, Uthe I, Esser C, Schiavi A, Ventura N, Krutmann J. HDAC inhibition improves autophagic and lysosomal function to prevent loss of subcutaneous fat in a mouse model of Cockayne syndrome. Sci Transl Med. 2018. https:\/\/doi.org\/10.1126\/scitranslmed.aam7510.","journal-title":"Sci Transl Med"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-02840-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-025-02840-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-02840-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T23:41:50Z","timestamp":1751586110000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-025-02840-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,4]]},"references-count":110,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2840"],"URL":"https:\/\/doi.org\/10.1186\/s40001-025-02840-9","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,4]]},"assertion":[{"value":"8 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"571"}}